Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. - Wikidata - wikimedia - TriplyDB

Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.

Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.

http://www.wikidata.org/entity/Q35974293

about

Adoptive T-cell therapy for cancer: The era of engineered T cells Vascular normalization and cancer immunotherapy Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells Targeting the tumor vasculature to enhance T cell activity Defects in the acquisition of tumor-killing capability of CD8+ cytotoxic T cells in streptozotocin-induced diabetic mice T cell exclusion, immune privilege, and the tumor microenvironment Selective toxicity of rose bengal to ovarian cancer cells in vitro Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth Intratumoral α-SMA enhances the prognostic potency of CD34 associated with maintenance of microvessel integrity in hepatocellular carcinoma and pancreatic cancer.Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis.Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy Vascular normalization as an emerging strategy to enhance cancer immunotherapy.Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice.Remodeling of tumor stroma and response to therapy.Monocytes and macrophages in cancer: development and functions Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment.The Pleiotropic Role of L1CAM in Tumor Vasculature Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome.Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.Exploiting cytokines in adoptive T-cell therapy of cancer.The therapeutic T-cell response induced by tumor delivery of TNF and melphalan is dependent on early triggering of natural killer and dendritic cells.Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells.Microfluidic models for adoptive cell-mediated cancer immunotherapies Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers.Genetically engineered mesenchymal stromal cells producing TNFα have tumour suppressing effect on human melanoma xenograft.The Physiological Role of Tumor Necrosis Factor in Human Immunity and Its Potential Implications in Spinal Manipulative Therapy: A Narrative Literature Review.Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy.Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer.Vascular-targeted TNFα and IFNγ inhibits orthotopic colorectal tumor growth Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.A model for cancer-suppressive inflammation Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.Celecoxib normalizes the tumor microenvironment and enhances small nanotherapeutics delivery to A549 tumors in nude mice.The tumor vessel targeting agent NGR-TNF controls the different stages of the tumorigenic process in transgenic mice by distinct mechanisms.Intratumoral TNFα improves immunotherapy.Engineered Mesenchymal Stem Cells as an Anti-Cancer Trojan Horse.

P2860

Q26800611-44BC424A-8DFD-4507-8334-EEB2C589D0A2 Q26827437-18567D16-D43A-459A-A587-B7A688CC414F Q26852287-F0CF1DA6-160F-4E92-8720-2E75D467620F Q27026329-A6B6ED84-E1D7-4EE5-BEB6-D7999F379F6C Q27335802-1126B7CB-2B77-4AB7-8358-BEE737251322 Q28259872-536EAC82-A628-4786-8AA0-E8F1F2D0A04D Q28271926-883A4BD7-DB2D-435D-BF5D-5AB0D182A7E0 Q30399006-743500E8-1D76-47A8-9CC4-F4B1314303AB Q30542073-C31C29D3-285D-4562-BB6F-3519B5C0AB2D Q30842176-0DEF5BE1-5F50-4967-8F76-37C55E73E589 Q34937019-F22F3421-A70E-43E3-BE81-0AD446AEC501 Q35056748-EFF86A3C-1629-4710-BB7D-4A4784251877 Q36378276-1481FBEC-6AEF-44FA-873C-D26E70F69986 Q36847357-7EC65B28-221F-4BEF-B3F3-957CA376A4F6 Q36938866-E4E99A0B-6317-4374-B7BA-71DB4507E799 Q37016995-29A53FE1-4C9D-46DB-8FE7-FBDFB0115085 Q37028772-FCFCCB9B-7D7E-45D1-A910-C7E016F12B24 Q37106787-8B4D8AE4-97F8-4E06-B92A-EBCF93D4C109 Q37516448-D258B71B-C6FD-4E35-AC1B-2321D84BFB70 Q37690651-5719FB41-8F43-4FDF-AB16-6EAE5CA243E4 Q38088013-91AB82BB-194D-498D-A133-59FEE902C71C Q38112578-A6493140-1006-4DE6-A77D-9D9A34B6B28E Q38525044-AA9BB463-41B5-4DBE-B30E-E50B0F88ABDD Q38716421-185DF891-65D9-4EB5-A3D6-1D3DD91D1DDB Q38728953-5AC4A736-BAB9-4489-9133-309868B0DE83 Q38805749-809D4D0B-A12C-4805-8256-F2BA8DC736E3 Q38835747-36D76FFF-5392-4617-961F-A44C526EFAC6 Q38872869-A71A00BC-DD76-4D95-8528-AA2D43493665 Q38910173-55367FF2-F805-4F06-B2D1-1942FD596A8F Q38962395-E653F164-2F16-4C60-B5FA-484C51A5F846 Q39173092-2EB0F96F-2D87-4D35-8F75-1DDF5E0EF536 Q39406918-DD951FE2-5DA0-45D9-9F44-E624049A5C9F Q39656460-DC747803-DA4E-45D3-A306-EB68A9999058 Q40674940-E1EB9CE2-FD37-4227-9448-BBAB91AA4DC4 Q41275639-CA9331A1-8F37-4039-A511-AE1C528A5EA5 Q41493082-EB542B3E-990A-4C8E-85DB-B004302FB33F Q41565207-C9459461-2B61-4798-97AB-7F41D9D9B4FC Q41577994-D7481523-B0A7-4657-AF84-01AAB9B86FB8 Q41767601-BD66A43C-76D7-427D-AF17-400ED40DD30C Q42391294-65857140-3D68-44C0-A031-8A890A33FE27

P2860

Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.

http://www.wikidata.org/entity/Q35974293

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.

@ast

Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.

@en

type

label

Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.

@ast

Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.

@en

prefLabel

Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.

@ast

Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.

@en

P1433

Q35974293-9AFBF639-3886-44FD-ADB3-9B4D5CA3F19E

P1476

Q35974293-6EC8E52D-0FF8-4385-9B31-FF753B9E38C7

P2093

Q35974293-8D318E84-4E86-4A78-8775-FF6FFE23C7C8

Q35974293-957C1B0F-3BCA-4BDA-A47A-21B843D9C4C8

P2860

Q35974293-1065830B-C334-4E35-923F-0124CD567686

Q35974293-1FFCD80C-185A-4D35-AE60-77B65E13C832

Q35974293-225E2230-9F53-480A-9E79-248B7C917621

Q35974293-2A883C51-DB9F-44C8-A9A9-B6200EBCF3BA

Q35974293-2C87C4B1-290C-4C74-B5AB-911E30EAD75F

Q35974293-32C73EBC-158F-4CF6-A1F1-D7DFB864FB71

Q35974293-36BE035D-57EF-42A1-AD42-DAD5F996294F

Q35974293-36C6B2F4-E494-4986-B425-0E9DEC4D82E7

Q35974293-3E52B62D-ECF3-46EE-8438-FCDF0481CC48

Q35974293-4893F36B-172C-4B54-9EE5-DA75E1E632FF

P304

Q35974293-3036FC8B-C167-4C6B-A9EB-5997C7F44A82

P31

Q35974293-535860FB-2303-4A40-9AF1-66CDCE65863B

P356

Q35974293-E292226F-5F5C-4CBA-9EC7-A483EC74891E

P407

Q35974293-E9683558-DF5C-4FAB-8430-E019B5E369A5

P433

Q35974293-75D08803-D08C-41A1-837E-F790F72642D5

P478

Q35974293-323EB9B4-087E-4467-9344-9457AF69644B

P50

Q35974293-2C729FEC-E04E-4125-81BE-3D0B1F2716D1

Q35974293-7C8B3754-6B8F-4408-A5E6-60B46FDA006A

P577

Q35974293-4B2B9D2E-874D-473D-B936-C7D81E37F81C

P5875

Q35974293-8D61E8E0-FC83-4B2F-AD45-424EC138A93D

P698

Q35974293-39A2D94C-BCB4-4BD4-BC0C-587BED084E1C

P921

Q35974293-D0F98D5A-CF58-4CA3-8D7D-7E4D32B059A2

P932

Q35974293-759E479E-44C3-4169-A6A5-6435BCA3AD1B

P356

PNAS.1118296109

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy

@en

P2093

Christine J Payne

http://www.w3.org/2001/XMLSchema#string

Juliana Hamzah

http://www.w3.org/2001/XMLSchema#string

P2860

HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF

Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis

Immunity, Inflammation, and Cancer

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis.

Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response.

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.

Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells.

Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts.

P304

7841-7846

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1118296109

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224871421

http://www.w3.org/2001/XMLSchema#string

P698

22547817

http://www.w3.org/2001/XMLSchema#string

P921

P932

3356673

http://www.w3.org/2001/XMLSchema#string